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Kernel Density Estimation was used to examine the lung disease by Age, Length of 
Stay and Total Charges by patient conditions. Text Miner in Enterprise Miner was
used to examine the data according to text strings of treatment procedures. Then we
predict the occurrence of lung cancer according to patient age, gender, days of stay
and total charge with the predictive modeling in Enterprise Miner. RESULTS: There
were 4718 observations related to lung cancer. There are more inpatient events starting 
at age 40, accelerating at age 50 and 55, and decreasing at 65. Patients with lung 
cancer had a higher probability of a stay of ﬁ ve days, which indicates that there was 
a higher probability of higher cost. We deﬁ ned clusters of procedures with a frequency
showing the effectiveness of treatment for patients. The Decision Tree is optimal with
a 22.9% misclassiﬁ cation rate in the testing set compared with other models in Enter-
prise Miner. CONCLUSIONS: Older patients are more likely to have lung cancers 
that would lead to a higher probability of longer stay and higher costs for the treat-
ment procedure. With text analysis on the procedure codes and KDE, it shows that
Levels IV and VI Surgical pathology, gross and microscopic examination are used for 
patients of higher risk with a higher cost compared to other procedures to diagnose
lung cancer.
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CLINICAL AND ECONOMIC OUTCOMES IN CANCER CHEMOTHERAPY
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(ESA) AT HEMOGLOBIN (HB) LEVELS < 10 G/DL
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OBJECTIVES: Recent changes to ESA prescribing information recommend initiation
at Hb levels  10 g/dL in cancer chemotherapy patients. Real world clinical and eco-
nomic outcomes data associated with this initiation range for the two FDA-approved
ESAs for this population [epoetin alfa (EPO) and darbepoetin alfa (DARB)] are sparse. 
METHODS: Data collected between December 2003 and September 2008 from 61 
U.S. oncology clinics from the Dosing and Outcomes Study of Erythropoietic Stimulat-
ing Therapies (D.O.S.E.) registry were assessed. Patients were included if they were
initiated on ESAs at baseline (BL) Hb  10 g/dL, age   18 years, and received  
2 doses of either EPO or DARB. Outcomes assessed included transfusion utilization, 
cumulative ESA doses, dose ratio (cumulative dose EPO: DARB) and ESA cost (based 
on cumulative ESA dose and December 2008 wholesale acquisition cost: EPO
$13.77/1000 Units, DARB $4.818/mcg). RESULTS: A total of 545 patients (237 EPO, 
308 DARB) were included. BL characteristics were similar between treatment groups
with regard to age, weight, cancer type and Hb. The mean administered dose was
42,610 Units in the EPO group and 259 mcg in the DARB group with a treatment
interval of 11.6 days and 19.4 days, respectively. Mean treatment duration was similar 
between groups (^65 days, P  0.34). The proportion of patients transfused was similar
between groups (^30%, P  0.70). Mean cumulative administered dose was 318,918
Units for EPO and 1,261 mcg for DARB corresponding to a dose ratio of 253:1 (Units 
EPO: mcg DARB). ESA cost was signiﬁ cantly lower in the EPO group compared to
the DARB group (EPO: $4392, DARB: $6075; P  0.001). CONCLUSIONS: In cancer
chemotherapy patients with Hb  10 g/dL prior to ESA initiation, transfusion utiliza-
tion was similar between groups. However, ESA costs were 28% lower in the EPO
group than the DARB group. These ESA-associated outcomes and cost data are 
informative to stakeholders treating cancer chemotherapy patients.
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COMPARISON OF INFECTION-RELATED HOSPITALIZATION RISK AND
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OBJECTIVES: Myelosuppressive chemotherapy can lead to neutropenia and increase 
infection risk. Myeloid growth factors are commonly used to treat/prevent neutrope-
nia. Sargramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF).
Unlike ﬁ lgrastim and pegﬁ lgrastim, which are granulocyte colony-stimulating factors 
(G-CSFs), sargramostim activates a broader range of myeloid lineage-derived cells. 
Therefore, GM-CSF might reduce infection risk more than G-CSFs. This study com-
pared real-world infection-related hospitalization rates and costs in patients using
G/GM-CSF for chemotherapy-induced neutropenia. METHODS: This retrospective
matched-cohort study analyzed nationally-representative health insurance claims in 
the US in 2000–2007. The sample population included patients who received chemo-
therapy and G/GM-CSF. G/GM-CSF treatment episodes began with the ﬁ rst adminis-
tration of G/GM-CSF and ended when a subsequent administration was 28 days 
after a prior administration. Sargramostim patients were matched 1:1 with ﬁ lgrastim 
and pegﬁ lgrastim patients based on gender and birth year. Outcomes included infec-
tion-related hospitalization rates and the associated costs. Hospitalization rates were 
analyzed using univariate and multivariate Poisson methods; covariates included
myelosuppressive agents received, tumor type, anemia, and comorbidities. RESULTS:
A total of 990 sargramostim-ﬁ lgrastim and 982 sargramostim-pegﬁ lgrastim pairs were 
analyzed. Cohorts had similar baseline characteristics, though differences were 
observed in the fraction of patients with a neutropenia diagnosis (sargramostim 65%, 
ﬁ lgrastim 57%, pegﬁ lgrastim 45%) and who received myelosuppressive agents (sar-
gramostim 54%, ﬁ lgrastim 48%, pegﬁ lgrastim 77%). Sargramostim patients experi-
enced infection-related hospitalizations about half as often as ﬁ lgrastim (p  0.04) or
pegﬁ lgrastim (p  0.06) patients. Multivariate analyses adjusted for confounding 
factors and found that sargramostim patients were 56% less likely to have infection-
related hospitalizations compared to ﬁ lgrastim and pegﬁ lgrastim patients (p  0.03 
for both). Infection-related hospitalization costs for sargramostim patients were $728/
patient/month and $226/patient/month less compared to ﬁ lgrastim (p  0.04) and 
pegﬁ lgrastim patients (p  0.01), respectively. CONCLUSIONS: Among patients with
chemotherapy-induced neutropenia, sargramostim use is associated with reduced risk 
of infection-related hospitalization and lower associated costs compared to ﬁ lgrastim
or pegﬁ lgrastim.
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SYSTEMATIC LITERATURE REVIEW TO ADDRESS BREAST CANCER 
ISSUES IN LOW-AND MIDDLE-INCOMES COUNTRIES FROM 1990–2008
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OBJECTIVES: Breast cancer prevention and control in low-and middle-income coun-
tries (LMCs) are critical emerging issues. Most LMCs lack sufﬁ cient resources for
screening, early detection, and treatment of breast cancer. However, little is known 
about what works to reduce the burden of breast cancer in low-resource settings or
how best to maximize public health interventions. The purpose of this study was to
assemble a knowledge base of studies in LMCs on breast cancer prevention, early 
detection, treatment, and palliative care that address issues of equity, access, and costs. 
METHODS: We conducted a systematic literature search via PUBMED and other 
computerized electronic databases. We classiﬁ ed each citation as relevant, peripherally 
relevant, not relevant, or unknown and maximized the criteria by using free-text words
and medical subject headings. All citations identiﬁ ed were independently reviewed by 
three members of the research team. Relevant studies were selected if they met inclu-
sion criteria: published in English or Spanish between January 1, 1990 and April 30,
2008. RESULTS: A total of 1907 citations were identiﬁ ed, of which, 53.2% were
excluded as “not relevant;” 27.1% were considered likely to be “relevant”; 5.5% were 
coded “peripherally relevant”; and 6.0% were “unknown”. All relevant articles (516) 
coming from 60 LMCs met the inclusion criteria and were abstracted. We found 80 
articles on East Asia/Paciﬁ c countries; 82 on Europe/Central Asia countries; 76 on
Latin American/Caribbean countries; 64 on Middle East/North Africa countries; 100
on South Asia countries; 71 on Sub-Saharan Africa countries; and 43 articles with no
region-speciﬁ c focus. We identiﬁ ed three articles on palliation and end-of-life care and 
a small number of articles reported cost data or economic analyses. CONCLUSIONS:
The review contains a wealth of practical information that would be extremely useful
to the myriad of clinicians and public health professionals working to prevent and 
treat breast cancer in LMCs.
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OBJECTIVES: Worldwide, the association of passive smoking with development of 
lung cancer has been ascertained. However, it remains unknown of the magnitude of 
the association in the Chinese population. We thus systematically reviewed the pub-
lished studies worldwide. METHODS: We searched Medline, EMBASE, and three 
other Chinese databases from their inception to June 30, 2008. We included case-
control and cohort studies that investigated the association of passive smoking with 
lung cancer, and that provided data on the magnitude of the association. Two reviewers 
screened the eligibility, assessed the extent of the bias, and extracted data independently.
We obtained the unadjusted and adjusted estimates of studies. We pooled the trial data 
using the random-effect model and explored the heterogeneity by the pre-speciﬁ ed 
variables. RESULTS: We included 20 studies (n  88,379). One was cohort study (n 
72,829) and 19 case-control studies (cumulative cases: 5977, and controls: 9573). 
Passive smoking increase the risk of lung cancer by 25% (OR  1.25, 95%CI  1.03 
to 1.47). Pooling of adjusted estimates of 10 case-control studies (2704 cases and 3495
controls) showed that the risk of lung cancer increased by 95% (1.95, 1.49 to 2.55).
In female life-long non-smokers, the passive smoking increased the risk of lung cancer
by 77% (1.77, 1.22 to 2.58, n  5685), and increased the risk of squamous cell carci-
noma and adenocarcinoma of female non-smokers by 99% (1.99, 1.19 to 3.33) and 
7% (1.05, 0.45 to 2.51). Because of the limited data, no signiﬁ cant dose-response
relationship was found between the risk of lung cancer and the exposure amounts,
durations and the initiating age. CONCLUSIONS: The increased risk of lung cancer 
associated with passive smoking in the Chinese population has been ascertained.
Passive smoking has a strong association with squamous cell carcinoma.
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OBJECTIVES: Worldwide, the association of smoking with development of lung 
cancer has been ascertained. However, it remains unknown of the magnitude of the 
association in the Chinese population. We thus systematically reviewed the published 
A38 Abstracts
studies worldwide. METHODS: We searched Medline, EMBASE, and three other 
Chinese databases from their inception to June 2008. We included case-control and
cohort studies that investigated the association of smoking with lung cancer, and that
provided data on the magnitude of the association. Two reviewers screened the eligibil-
ity, assessed the extent of bias, and extracted data independently. We obtained unad-
justed and adjusted estimates of studies. We pooled the trial data using random-effect 
model and explored the heterogeneity by the pre-speciﬁ ed variables. RESULTS: We 
included 45 (n  71,869), 4 of which were cohort studies (n  48,250) and 41 case-
control studies (cumulative cases: 10,268, and controls: 13,351). Smoking increased 
the risk of lung cancer by 137% (OR 2.37, 95%CI 1.95 to 2.88). Pooling of adjusted 
estimates of in 32 studies showed that the risk of lung cancer was increased by 181% 
(2.81, 2.31 to 3.42). No gender difference was found in the association (15 studies): 
ORs were 3.19 (2.51 to 4.06) in male and 2.98 (2.29 to 3.89) in female (interaction
p  0.1). The risks were statistically different in different type of lung cancer: aden-
carcinoma 1.81 (1.23 to 2.66), squamous cell carcinoma 7.07 (2.34 to 21.38), and
small cell lung cancer 7.98 (4.22 to 15.11). The increased amount of smoking 
increased the risk of lung cancer (coef. 0.27, 0.03 to 0.51). No signiﬁ cant dose-
response was found between the risk of lung cancer and the duration and initiating 
age of smoking. CONCLUSIONS: The association between smoking and lung cancer
has been ascertained in the Chinese population. Pronounced heterogeneity in risks of 
lung cancer was found in different type of lung cancer and amount of smoking.
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OBJECTIVES: Increasing attention has been paid to team-based approaches to the 
management of patients with advanced prostate cancer (PCa). It is not known whether 
the timing of specialist contacts relative to treatment initiation is associated with sur-
vival. This study examines whether patients with visits to a medical oncologist/hema-
tologist (MOH) before treatment have better survival outcomes than those who see a
MOH after treatment begins. METHODS: A retrospective analysis of linked Surveil-
lance, Epidemiology, and Endpoints (SEER) – Medicare data included patients diag-
nosed with Stage IV PCa between 1994 and 2002 (age  65 years) who received 
treatment and a referral. Treatment was deﬁ ned as the receipt of orchiectomy, hormone 
therapy, chemotherapy, or radiation at any time following diagnosis. A referral was 
deﬁ ned as a post-diagnosis visit to an urologist followed by a visit to a MOH. The 
key covariate identiﬁ ed patients referred prior to treatment initiation. Colon cancer – 
speciﬁ c mortality models controlled for potential confounders including demographic, 
clinical, continuity-of-care, and ecological measures. RESULTS: A total of 2075
patients with Stage IV PCa met the inclusion criteria. The average age in the sample 
was 75 years and 83% were White. Seven percent of patients visited both specialists 
before receiving treatment. Referral visits prior to the start of treatment were associ-
ated with a reduction in the relative risk of disease – speciﬁ c mortality (HR: 0.7; 0.5 
– 0.9, p  0.02) in the full sample and in a propensity-matched sample (HR: 0.6; 0.4 
– 0.9, p  0.006). CONCLUSIONS: As treatment options for advanced stage PCa
evolve, patients may beneﬁ t from contact with a team of specialists. We ﬁ nd that there 
is a survival beneﬁ t associated with referrals that occur prior to treatment initiation. 
The results suggest that the timing of specialist visits is important for PCa survival. 
Further studies on referral patterns are needed to validate these results.
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THE PREVALENCE AND COSTS OF ADVERSE METABOLIC EFFECTS OF
ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS
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OBJECTIVES: Atypical antipsychotics are currently the most frequently prescribed
class of drugs for schizophrenia. These drugs appear to be associated with varying
degrees of metabolic adverse effects. We conducted a retrospective clinical study to
evaluate the adverse metabolic effects of antipsychotic medications in schizophrenic 
patients in Taiwan population. METHODS: This is a retrospective observational 
study. A total of 431 outpatients who were diagnosed with schizophrenia and taken
clozapine or olanzapine or risperidone or haloperidol for more than one year were
included in this study. We excluded those who took other drugs known to affect 
glucose metabolism (including á, â-blockers, thiazide diuretics, phenytoin, valproate,
and corticosteroids), and those who were diagnosed with diabetes mellitus and hyper-
lipidemia at the initial time of study. The changes of blood lipids and fasting blood 
glucose levels noted in the medical records were reviewed and analyzed. RESULTS:
The results indicated that 298 outpatients showed weight gain after 6^8 months of 
medications. 83.3%(60/72) of risperidone-treated patients had experienced signiﬁ cant 
weight gain as compared with 48.8%(40/82) of clozapine and 4% (2/50) haloperidol 
treated patients (p  0.001). The potential risk of increased fasting blood glucose, 
cholesterol, and triglyceride levels for risperidone-treated patients were 50.5 o 4.2%, 
13.9 o 5.6% and 53.8 o 4.2%, respectively. 48 patients need additional drugs to regu-
late the increased metabolic levels, such as atorvastatin for increased triglyceride levels
and glucophage for increased blood glucose level. The extra medications expenditure 
used to regulate the adverse effect was about NT 13 million each year. CONCLU-
SIONS: The atypical antipsychotic drugs can cause adverse metabolic effects. Ameri-
can Diabetes Association (ADA) suggested to monitor patients’ body weight, fasting 
blood glucose, and lipid proﬁ le for those who are prescribed atypical antipsychotics.
Additionally, the diet control and regular exercise should be suggested to patients who
have already been getting weight in the treatment of atypical antipsychotics.
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OBJECTIVES: The aim of this study was to compare the effectiveness and servival
rate of cetuxiamb plus chemotherapy with the traditional chemotherapy alone in the 
treatment of metastatic colorectal cancer.( mCRC). METHODS: This is a retrospective 
observational study which was conducted from January 2004 to December 2008. 
Hospitalized patients diagnosed with mCRC and treated with chemotherapy regimen
of FOLFIRI (irinotecan/ 5-ﬂ uorouracil/ leucovorin) plus cetuximab or patients treated 
with FOLFIRI or FOLFOX (oxaliplatin/5-ﬂ uorouracil/leucovorin) chemotherapy 
regimen alone for a course of 1 year were recruited. The medical records for all 
patients recruited were evaluated by clinical pharmacist. T-test was used for analysis. 
RESULTS: A total of 143 patients were identiﬁ ed. Sixty-ﬁ ve patients were treated with 
FOLFIRI (irinotecan/ 5-ﬂ uorouracil/ leucovorin) plus cetuximab and seventy-eight 
patients were treated with FOLFIRI or FOLFOX alone. The results showed that total 
50 patients treated with FOLFIRI combined with cetuximab were survived about 17.3 
months, survival rate was 64%; whereas, total of 65 patients treated with FOLFIRI
or FOLFOX alone were survived about 12.9 months, survival rate was 41%. By using 
chemotherapy combined with cetuximab, the survival rate increased about 4.4 
momths as compared to the chemogtherapy alone. The difference of survival rate 
between two groups is statistical signiﬁ cant. (p value is 0.018). CONCLUSIONS: The 
preliminary result indicated that chemotherapy plus cetuximab is more effective as
compared to chemotherapy alone for mCRC patients. However, cetuximab is more
expensive target chemotherapeutic drugs in our country, therefore, evaluation on 
direct medical costs of two regimens is indispensable and data will be completed in 
the near future.
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OBJECTIVES: Recommended treatment duration of atrophic vaginitis in postmeno-
pausal women with vaginal estrogen (VE) is currently limited to 6–12 months, the
length of clinical trials conducted to date, due to concerns of potential development
of endometrial carcinoma. In practice, many women use VE longer. This study exam-
ines the association between VE use and risk of endometrial carcinoma over a 3 year 
follow-up period among Medicaid enrollees. METHODS: A retrospective cohort 
study was conducted using North Carolina Medicaid prescription and medical claims 
between January 1998 and December 2007. The study included women ages 18–64 
years with a prescription claim for VE (cream, tablet, and ring forms) or a diagnosis 
of atrophic vaginitis (identiﬁ ed by ICD-9 code 627.3). Demographic factors included
age and race (African American, white, or other). Comorbidity risk adjustment was
determined using the Charlson-Deyo method. Multiple logistic regression was per-
formed to assess the association of VE use and endometrial carcinoma adjusting for 
age, race, and comorbidities. RESULTS: A total of 770 patients prescribed VE (mean
age 50.1 years /8.4) and 881 patients diagnosed with atrophic vaginitis but not 
treated with VE (mean age 49.4 years /9.8) were identiﬁ ed in the database. Ten 
cases of uterine carcinoma were identiﬁ ed among the VE patients; 11 cases among 
women not prescribed VE. Logistic regression results showed no signiﬁ cant difference
in the occurrence of endometrial carcinoma between women on VE therapy and those 
not on VE therapy (OR  1.11, 95%CI: 0.47–2.65, P  0.814). Older age was the 
only signiﬁ cant predictor of uterine carcinoma (OR  1.11, 95%CI: 1.03–1.20, P 
0.008); i.e., for a ten-year increase in age, odds of endometrial carcinoma increased 
by a factor of 2.8. CONCLUSIONS: With three years of follow-up showed no associa-
tion between VE exposure and endometrial carcinoma. Increasing age was found to 
be the only signiﬁ cant risk factor.
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OBJECTIVES: The phase III trial AVOREN demonstrated that BEV  interferon-
alpha2a (IFN) prolongs progression-free survival compared with IFN  placebo in 
patients with untreated mRCC [Escudier, Lancet 2007]. The protocol speciﬁ ed that 
the recommended dose of IFN (9MIU 3x/week) could be lowered to 6 or 3MIU for 
grade q3 adverse events (AEs) attributable to IFN or other investigator-deﬁ ned 
reasons. A retrospective analysis of AVOREN showed that lower-dose (LD) IFN in 
combination with BEV improves tolerability and maintains clinical beneﬁ t [Melichar, 
Ann Oncol 2008]. We report here the costs of managing side effects of BEV  LD IFN 
